Schizophrenia.com

Aripiprazole lauroxil - Long Acting Antipsychotic - use every two months


#1

Alkermes plc (ALKS: Quote) announced new developments related to its late-stage product candidates in its proprietary central nervous system or CNS pipeline.

The company unveiled aripiprazole lauroxil two-month, a new product candidate addition to its portfolio of atypical antipsychotics for the treatment of schizophrenia. If approved, aripiprazole lauroxil two-month would be the first and only long-acting atypical antipsychotic medication dosed every two months. This new two-month product candidate is designed to provide physicians and patients with an even longer dosing option than the once-monthly formulation of aripiprazole lauroxil, which is currently completing the phase 3 study, with topline results expected in the first half of 2014.

The aripiprazole lauroxil two-month product candidate is designed to offer physicians and patients a dosing option that is not currently available, and Alkermes plans to begin clinical testing in 2014. Both the one-month and two-month forms of aripiprazole lauroxil are long-acting injectable medications that, once in the body, convert into aripiprazole, a molecule that is commercially available under the name ABILIFY, and both utilize the company’s proprietary LinkeRx technology.

http://www.rttnews.com/2248204/alkermes-reports-new-developments-on-late-stage-central-nervous-system-pipeline.aspx


#2

More news on this here: